GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Hospital readmissions, ER visits and major complications were all less likely when TAVR patients used a smartphone app to assist with their recovery. 

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

Endovascular procedure volumes surged 427% among cardiologists between 2010-2018, compared to a 125% uptick among radiologists. 

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

AI was one of the biggest stories at the American Heart Association’s Scientific Sessions 2023 conference in Philadelphia. Researchers presented new data about heart attack care, voice recognition algorithms, digital stethoscopes and more.